The "Fast Money" traders take a look at today's biggest market movers.» Read More
The chief executive explains why his company took such a hit after Wednesday's earnings call.
Economic worries are still hanging over the market, and CNBC went straight to the top to get some answers.
In late July at a big scientific conference in Chicago, I reported on new, positive data on Medivation's experimental Alzheimer's drug Dimebon (dim-uh-bahn).
There's an interesting theory when it comes to the SUV market. It goes like this: now is the best time to buy an SUV because the used market has bottomed out and prices will soon start going up. The more I've heard this, the more I've talked with dealers. And you know what their reaction is? A good laugh.
Three years after Hurricane Katrina, New Orleans' deputy chief of Army Corps of Engineers comments on how the city is preparing for future storms. Plus, ClimateMaster introduces a device that uses geothermal power. Following are today's top videos:
See, even mighty Toyota Motor is shifting into a slower gear. This morning in Tokyo, the company gave its business outlook for 2009 and beyond. It was mixed -- which is not surprising, given the economy. Here's Toyota's plan to stay ahead.
Germany's Chancellor Angela Merkel topped Forbes magazine's list of the world's 100 most powerful women for the third year running, while U.S. Secretary of State Condoleezza Rice slipped to seventh from fourth last year.
SEC Chairman Christopher Cox talks about Fannie Mae and Freddie Mac's stock movements while Sin City's gambling industry faces an economic earthquake. Following are today's top videos:
Yes, the stock took a hit on bad earnings. But Cramer's expecting a triumphant return.
Since I've started this blog I've have had people react strongly to some of the things I've said. But NOTHING compares to the e-mails I've read after advocating the need for Federal loans to help the Big 3 automakers re-tool and rebuild their operations.
After the closing bell Monday, Eli Lilly and Amylin Pharmaceuticals announced that they're going to hold a conference call for analysts and investors about their diabetes drug Byetta. Why?
The expected business coming from the lastest Medicare bill could be one reason to.
Talk about timely direct-to-consumer advertising. Last week ,I blogged about AstraZeneca's new ad campaign for FluMist and its tie-in with the back-to-school shopping season. Well, now the drugmaker is getting political.
Dick Bove, analyst at Landenburg Thalmann gives Lehman Brothers a "buy" rating and the Heinz CEO talks about his company's strong earnings. Following are today's top videos:
A proxy battle has been raging at this company for some time. Have the two sides finally made peace?
Overseas sales are driving this company. And it looks like this is just the beginning.
Shares of Genentech are taking another little breather after rising to around 99 bucks on speculation that a higher offer is coming from Roche. Analyst guestimates of the ultimate takeout price -- if, indeed there is one -- are generally above a hundred dollars a share.
Don't look now, but something is coming back: deals. Not just little ones. Pretty decent deals. GM, Toyota and Mazda are currently running some of the more prominent marketing campaigns. But make no mistake, almost all the automakers are throwing more money and more generous financing terms behind their new models.
With only 10% market penetration, there's still plenty of room left to grow.
The "bond kings" gather to comment on the credit crunch while the CEO of BorgWarner says his company has come up with a technology that improves fuel efficiency and lowers emissions for automobiles. Following are today's top videos: